Quoin Pharmaceuticals Ltd
QNRX
Company Profile
Business description
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Contact
42127 Pleasant Forest Court
AshburnVA20148-7349
USAT: +1 703 980-4182
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,004.90 | 14.70 | 0.16% |
| CAC 40 | 8,428.62 | 65.48 | 0.78% |
| DAX 40 | 25,212.08 | 200.73 | 0.80% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,682.80 | 96.89 | 0.92% |
| HKSE | 24,892.66 | 239.63 | -0.95% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 66,115.60 | 116.59 | -0.18% |
| NZX 50 Index | 13,763.18 | 107.15 | 0.78% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,823.00 | 16.50 | 0.19% |
| SSE Composite Index | 3,867.03 | 2.67 | 0.07% |